Toll-Like Receptor 2 (TLR-2) Gene Polymorphisms in Type 2 Diabetes Mellitus.
Diabetes
Inflammation
Polymorphism
TLRs
Journal
Cell journal
ISSN: 2228-5806
Titre abrégé: Cell J
Pays: Iran
ID NLM: 101566618
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
25
09
2017
accepted:
13
12
2017
entrez:
21
8
2018
pubmed:
21
8
2018
medline:
21
8
2018
Statut:
ppublish
Résumé
Innate immunity factors are associated with type 2 diabetes (T2DM) and its complications. Therefore, T2DM has been suggested to be an immune-dependent disease. Elevated fasting glucose level and higher concentrations of innate immunity soluble molecules are not only related with insulin resistance, but inflammation is also an important factor in beta cell dysfunction in T2DM. Toll-like receptor 2 (TLR-2), which has an important role in inducing innate immune cells, is thought to have suppressive roles on immune responses in T2DM. We therefore aimed to investigate the possible role of TLR-2 del -196-174 and Arg753Gln variants in T2DM pathogenesis. This study was designed as a case-control study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to genotype the two variants in 100 T2DM patients and 98 agematched controls. We found significantly higher frequencies of TLR-2 del -196-174 DD genotype (P=0.003), ID genotype (P=0.009) and D allele (P=0.001) in patients compared with controls. In addition, the II genotype (P=0.001) and the I allele (P=0.003) frequencies were elevated in healthy controls. We did not find any significant differences in frequency distribution for the Arg753Gln variant in study groups. We suggest that carrying the D allele of the TLR-2 del -196-174 variant may be related as a risk factor for T2DM.
Identifiants
pubmed: 30124003
doi: 10.22074/cellj.2019.5540
pmc: PMC6099132
doi:
Types de publication
Journal Article
Langues
eng
Pagination
559-563Informations de copyright
Copyright© by Royan Institute. All rights reserved.
Déclaration de conflit d'intérêts
There is no conflict of interest in this study.
Références
Genet Mol Res. 2016 Apr 25;15(2):
pubmed: 27173229
J Biol Chem. 2012 Nov 2;287(45):38327-37
pubmed: 22992740
PLoS One. 2013 Dec 20;8(12):e82858
pubmed: 24376595
Cell Metab. 2013 Jun 4;17(6):873-82
pubmed: 23747246
Diabetologia. 2010 Sep;53(Suppl 1):S7-533
pubmed: 20690007
Ann N Y Acad Sci. 2008 Dec;1150:123-32
pubmed: 19120280
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
Diabetologia. 2005 Jun;48(6):1038-50
pubmed: 15864529
Int J Immunogenet. 2011 Dec;38(6):519-23
pubmed: 21902816
Diabetes Res Clin Pract. 2010 Jan;87(1):4-14
pubmed: 19896746
Diabetes Care. 2010 Apr;33(4):861-8
pubmed: 20067962
Int J Cancer. 2012 Mar 15;130(6):1470-5
pubmed: 21500195
J Am Coll Cardiol. 2003 Apr 2;41(7):1071-7
pubmed: 12679203
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Int Immunopharmacol. 2011 Nov;11(11):1747-51
pubmed: 21771668
Eur J Epidemiol. 2013 Feb;28(2):169-80
pubmed: 23407904
Diabetes Care. 2004 Mar;27(3):813-23
pubmed: 14988310
J Neuroinflammation. 2011 Oct 11;8:136
pubmed: 21989233
Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S421-6
pubmed: 16237641
Biochem Biophys Res Commun. 2009 Oct 30;388(4):621-5
pubmed: 19686699
Cancer Sci. 2007 Nov;98(11):1790-4
pubmed: 17711514
Diabetologia. 2009 Aug;52(8):1665-8
pubmed: 19455302
Genet Mol Res. 2015 Jul 31;14(3):8694-705
pubmed: 26345801
Medicine (Baltimore). 2017 Apr;96(17):e6760
pubmed: 28445304
Nat Med. 2005 Feb;11(2):183-90
pubmed: 15685173
J Biol Chem. 2009 Feb 27;284(9):5915-26
pubmed: 19122198
Diabetologia. 2010 Aug;53(8):1795-806
pubmed: 20407745
J Leukoc Biol. 2014 Jan;95(1):47-52
pubmed: 24018354
Mol Biol Rep. 2012 Jul;39(7):7263-9
pubmed: 22311043
Cell Mol Biol Lett. 2016 Jul 28;21:2
pubmed: 28536605
J Endocrinol Invest. 2008 Aug;31(8):694-9
pubmed: 18852529